CPC-111 metabolic energy intermediate data

CYPR presented results from an ongoing double-blind, placebo-controlled Phase II trial in the U.K. in CABG patients, showing statistically significant reductions in heart injury

Read the full 248 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE